Equities research analysts at UBS Group initiated coverage on shares of CG Oncology (NASDAQ:CGON - Get Free Report) in a research note issued on Thursday, MarketBeat Ratings reports. The firm set a "buy" rating and a $60.00 price target on the stock. UBS Group's target price suggests a potential upside of 64.61% from the stock's current price.
Several other research firms have also recently issued reports on CGON. Roth Mkm started coverage on CG Oncology in a report on Tuesday, August 27th. They set a "buy" rating and a $65.00 price objective on the stock. Bank of America restated a "buy" rating and issued a $65.00 price target on shares of CG Oncology in a report on Tuesday, October 8th. Royal Bank of Canada started coverage on shares of CG Oncology in a report on Monday, September 23rd. They set an "outperform" rating and a $66.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a report on Tuesday, September 17th. Finally, Roth Capital raised shares of CG Oncology to a "strong-buy" rating in a research note on Tuesday, August 27th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $63.88.
Get Our Latest Stock Analysis on CG Oncology
CG Oncology Price Performance
Shares of CG Oncology stock traded up $0.84 during mid-day trading on Thursday, hitting $36.45. 226,408 shares of the stock were exchanged, compared to its average volume of 669,419. CG Oncology has a twelve month low of $25.77 and a twelve month high of $50.23. The company has a 50-day simple moving average of $36.60 and a 200 day simple moving average of $34.83.
CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.11 million for the quarter. Equities analysts predict that CG Oncology will post -1.47 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Hong Fang Song sold 650,455 shares of the firm's stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $35.36, for a total value of $23,000,088.80. Following the transaction, the director now owns 586,982 shares of the company's stock, valued at approximately $20,755,683.52. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Institutional Investors Weigh In On CG Oncology
Large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. purchased a new position in CG Oncology in the 1st quarter worth approximately $102,000. California State Teachers Retirement System acquired a new position in shares of CG Oncology during the first quarter worth $103,000. Profund Advisors LLC purchased a new position in shares of CG Oncology in the second quarter valued at $300,000. BNP Paribas Financial Markets acquired a new stake in CG Oncology during the 1st quarter valued at $492,000. Finally, SG Americas Securities LLC purchased a new stake in CG Oncology during the 3rd quarter worth $664,000. Institutional investors and hedge funds own 26.56% of the company's stock.
About CG Oncology
(
Get Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Further Reading
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
